D. E. Shaw & Co. Inc. Has $1.69 Million Stock Position in Bioventus Inc. (NYSE:BVS)

D. E. Shaw & Co. Inc. reduced its position in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 50.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 160,656 shares of the company's stock after selling 160,974 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.20% of Bioventus worth $1,687,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its holdings in Bioventus by 11.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company's stock worth $4,571,000 after acquiring an additional 45,182 shares during the period. Principal Financial Group Inc. grew its holdings in Bioventus by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company's stock worth $202,000 after acquiring an additional 1,652 shares during the period. Vanguard Group Inc. grew its holdings in Bioventus by 18.7% during the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company's stock worth $25,852,000 after acquiring an additional 388,174 shares during the period. Barclays PLC grew its holdings in Bioventus by 31.0% during the 4th quarter. Barclays PLC now owns 66,337 shares of the company's stock worth $696,000 after acquiring an additional 15,683 shares during the period. Finally, Spire Wealth Management bought a new position in shares of Bioventus during the fourth quarter worth $402,000. 62.94% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BVS shares. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th.

Insiders Place Their Bets

In other news, CFO Mark Leonard Singleton sold 3,875 shares of the business's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total transaction of $29,333.75. Following the transaction, the chief financial officer now directly owns 141,088 shares in the company, valued at $1,068,036.16. The trade was a 2.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 13,330 shares of company stock valued at $115,291 in the last three months. 32.90% of the stock is currently owned by corporate insiders.

Bioventus Stock Up 1.3%

NYSE:BVS traded up $0.09 on Tuesday, hitting $6.62. 41,373 shares of the company's stock were exchanged, compared to its average volume of 365,953. The firm has a 50-day moving average price of $7.72 and a 200-day moving average price of $9.58. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 52 week low of $5.28 and a 52 week high of $14.38. The company has a market cap of $543.38 million, a P/E ratio of -10.84 and a beta of 0.95.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.